Regeneron (REGN), Sanofi (SNY) Report Publication of Results from Two Positive Phase 3 Trials of Dupixent (dupilumab) in Severe Chronic Rhinosinusitis with Nasal Polyps

September 20, 2019 7:01 AM
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (NYSE: SNY) today announced that The Lancet has published detailed positive results from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles